T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Bloom Energy
BE
$69.6B
| $8.8M | ﹤0.01% |
470,083
-162,746
| -26% | -$3.44M |
|
1427
Protagonist Therapeutics
PTGX
$9.84B
| $8.71M | ﹤0.01% |
491,641
-494,613
| -50% | -$21.1M |
|
1428
Quince Therapeutics
QNCX
$31.8M
| $8.67M | ﹤0.01% |
473
+276
| +140% | +$4.39M |
|
|
NUAN
1429
DELISTED
Nuance Communications, Inc.
NUAN
| $8.62M | ﹤0.01% |
156,514
-13,301
| -8% | -$731K |
|
1430
Silicon Laboratories
SLAB
$7.3B
| $8.59M | ﹤0.01% |
61,301
-1,369
| -2% | -$205K |
|
1431
NNN REIT
NNN
$8.79B
| $8.59M | ﹤0.01% |
198,877
-91,119
| -31% | -$4.29M |
|
1432
Stoke Therapeutics
STOK
$2.02B
| $8.59M | ﹤0.01% |
337,582
-49,841
| -13% | -$1.39M |
|
|
VIRX
1433
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $8.57M | ﹤0.01% |
+1,068,812
| New | +$10.5M |
|
1434
Markel Group
MKL
$22.8B
| $8.55M | ﹤0.01% |
7,152
-582
| -8% | -$718K |
|
1435
Sylvamo
SLVM
$1.53B
| $8.49M | ﹤0.01% |
+259,741
| New | +$8.08M |
|
|
MTEM
1436
DELISTED
Molecular Templates, Inc.
MTEM
| $8.33M | ﹤0.01% |
82,730
-187
| -0.2% | -$19.3K |
|
|
OHPAU
1437
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| $8.22M | ﹤0.01% |
831,549
| – | – |
|
|
CELL
1438
DELISTED
PhenomeX Inc. Common Stock
CELL
| $8.17M | ﹤0.01% |
417,730
-370,962
| -47% | -$14.1M |
|
1439
Jones Lang LaSalle
JLL
$17B
| $8.15M | ﹤0.01% |
32,843
-2,631
| -7% | -$601K |
|
|
NGM
1440
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $8.09M | ﹤0.01% |
384,716
-49,142
| -11% | -$1.08M |
|
1441
JetBlue
JBLU
$2.18B
| $8.09M | ﹤0.01% |
528,866
+336,176
| +174% | +$5.16M |
|
1442
eHealth
EHTH
$39.7M
| $8.07M | ﹤0.01% |
199,340
-34,050
| -15% | -$1.59M |
|
1443
Royal Gold
RGLD
$19.7B
| $8.07M | ﹤0.01% |
84,527
+541
| +0.6% | +$60.6K |
|
|
FRONU
1444
DELISTED
Frontier Acquisition Corp. Units
FRONU
| $8.04M | ﹤0.01% |
814,927
| – | – |
|
1445
Orchestra BioMed
OBIO
$266M
| $7.99M | ﹤0.01% |
807,765
-2,373
| -0.3% | -$23.4K |
|
1446
Plug Power
PLUG
$3.21B
| $7.94M | ﹤0.01% |
310,733
+8,909
| +3% | +$239K |
|
1447
Berkshire Hathaway Class A
BRK.A
$1.09T
| $7.82M | ﹤0.01% |
19
| – | – |
|
1448
Vroom Inc
VRM
$52.1M
| $7.79M | ﹤0.01% |
4,413
+4,332
| +5,348% | +$11M |
|
1449
Trinity Capital Inc.
TRIN
$1.73B
| $7.77M | ﹤0.01% |
482,773
+55,200
| +13% | +$841K |
|
|
CMRC
1450
Commerce.com Inc Series 1
CMRC
$179M
| $7.73M | ﹤0.01% |
152,733
+142,764
| +1,432% | +$8.7M |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.